HutchMed (00013) announced the publication of the SACHI Phase III study results in The Lancet.

HUTCHMED (00013) announced today that the results of the SACHI Phase III study have been published in The Lancet. SACHI is a Phase III study of the combination therapy of savolitinib (Orpathys) and osimertinib (Tagrisso) for the treatment of locally advanced or metastatic non-small cell lung cancer patients with EGFR mutation-positive disease progression after first-line treatment with an EGFR tyrosine kinase inhibitor (TKI) and MET amplification. Savolitinib is a potent, highly selective oral MET TKI co-developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca. Osimertinib is an irreversible third-generation EGFR TKI. Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025. Professor Lu Shun, the principal investigator of the SACHI study and Director of the Shanghai Lung Cancer Center at Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, stated: "The data from the SACHI study published in The Lancet provide compelling evidence that the combination therapy of savolitinib and osimertinib can significantly improve the treatment outcomes of patients with EGFR-mutated non-small cell lung cancer with MET amplification. These results highlight the ability of this combination therapy to address the key resistance mechanism of MET amplification, providing clinically meaningful improvements for this challenging patient population. It is particularly encouraging to observe consistent efficacy in patients previously treated with third-generation EGFR TKIs. The combination therapy of savolitinib and osimertinib offers a convenient and well-tolerated treatment option for patients in need of new therapies." Professor Wang Jie from the Cancer Hospital of the Chinese Academy of Medical Sciences is also a principal investigator of the SACHI study.